Loading
Life sciences · Journal article
International Journal of Nanomedicine · October 31, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Nanoplatform-based combination therapy offers a promising route for enhanced cancer therapy. Despite the advance of nanomedicine, the precise subcellular co-delivery and controlled release of combinatorial therapeutic agents remain a significant challenge. Methods: Herein, a near-infrared (NIR)-responsive mitochondria-targeted nanoplatform (HTL@CIC) was firstly developed for combined cancer therapy. Briefly, curcumin (CUR) and indocyanine green (ICG) were co-loaded into a lipid-coated covalent organic framework (COF), followed by surface modification with a hyaluronic acid-triphenylphosphonium conjugate (HT). The characterization, release behavior, cellular uptake, mitochondrial targeting, anticancer activity, and safety of the developed nanoparticle were investigated. Moreover, the underlying mechanisms of tumor targeting ability and anticancer effect were explored. Results: The HTL@CIC exhibited good stability and improved photothermal performance. Moreover, it showed prolonged circulation, while the HT moiety simultaneously conferred CD44-mediated tumor targeting and triphenylphosphonium-directed mitochondrial accumulation. Besides, NIR laser irradiation could trigger a rapid release of CUR and ICG, which subsequently produced an enhanced antitumor effect combining chemotherapy and photothermal therapy (PTT). Both in vitro and in vivo studies demonstrated the superior antitumor activity of HTL@CIC. The improved antitumor outcome likely resulted from reactive oxygen species (ROS) overproduction and mitochondrial damage. Furthermore, HTL@CIC exhibited favorable erythrocyte compatibility as well as good biosafety in the mice and zebrafish. Conclusion: The NIR-responsive HTL@CIC achieves tumor- and mitochondria-targeted controlled release of CUR and ICG, enhancing anticancer efficacy with good safety. Therefore, this developed platform may offer a novel and promising strategy for subcellular precision cancer therapy. Keywords: covalent organic framework, curcumin, indocyanine green, tumor therapy, nanomedicine